Unique ID issued by UMIN | UMIN000029504 |
---|---|
Receipt number | R000033711 |
Scientific Title | Balloon occluded transarterial chemoembolization using miriplatin in HCC: A Multicenter, Clinical Phase II study |
Date of disclosure of the study information | 2017/10/11 |
Last modified on | 2025/04/20 01:39:17 |
Balloon occluded transarterial chemoembolization using miriplatin in HCC: A Multicenter, Clinical Phase II study
B-TACE study
Balloon occluded transarterial chemoembolization using miriplatin in HCC: A Multicenter, Clinical Phase II study
B-TACE study
Japan |
Hepatocellular carcinoma
Hepato-biliary-pancreatic medicine | Radiology |
Malignancy
NO
To evaluate effectiveness and safety of balloon occluded transarterial chemoembolization using miriplatin in HCC.
Safety,Efficacy
Confirmatory
Pragmatic
Phase II
Response rate in largest tumor (3 months after treatment)
Adverse events, progression-free survival, overall survival, response rate of HCC treated by B-TACE (3 months), achievement rate of B-TACE
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Balloon occluded transarterial chemoembolization using miriplatin
18 | years-old | <= |
Not applicable |
Male and Female
1). Histologically or clinically confirmed hepatocellular carcinoma. The largest tumor is<= 5cm. The number of HCC in the patient is within 4 (local recurrent lesion is not allowed).
2). Without major portal invasion (Vp3 or Vp4)
3). Target lesion is not treated.
4). Child-Pugh A or B
5). not the candidate of surgery
6). Adequate organ functions: bone marrow, Heart, renal function (14 days before entry)
Neutro =>1,500/mm3
HGB =>8.5g/dl
Plt >=5.0x104/mm3
T-Bil <=2.0mg/dl
AST <= 5 times ULN
ALT <= 5 times ULN
PT% > 50%
Serum Cre <=1.5 times ULN
7). Over 18 years old
8). ECOG Performance Status 0 or 1
9). Expected survival time over 12 weeks
10). Written informed consent
1) Bile duct injury(bile duct dilatation), reconstruction of the biliary tract history, history of endoscopic biliary treatment
2) Severe arterio-portal shunting
3) Severe arterial stenosis or obstruction in CECT or AAG
4) Severe ascites or pleural effusion
5) Major portal invation (Vp3 or Vp4)
6) Severe complication (cardiac failure, arrhythmia, angina pectoris, myocardial infarction within 6 months, double cancer, active infection, gastrointestinal bleeding, severe hepatic encephalopathy, severe allergya for
contrast media or medicine)
7) Pregnant, nursing or possible pregnant woman
8) Qualified ineligible patients being this clinical trial by responsible doctor
52
1st name | Koichiro |
Middle name | |
Last name | Yamakado |
Hyogo College Of Medicine College
Department of Radiology
663-8501
1-1 Mukogawa-cho, Nishinomiya, Hyogo, Japan
0798-45-6111
yamakado47@gmail.com
1st name | Akira |
Middle name | Akira |
Last name | Yamamoto |
Osaka Metropolitan Univercity
Department of Radiology
545-8585
1-4-3, Asahi-machi,Abebo-ku, Osaka, Osaka
06-6645-3831
loveakirayamamoto@gmail.com
The Japanese Society for Transcatheter Hepatic Arterial Embolization
The Japanese Society for Transcatheter Hepatic Arterial Embolization
Other
Osaka Public University Medical Research Ethics Review Committee
1-4-3, Asahi-machi,Abebo-ku, Osaka, Osaka
06-6645-3456
loveakirayamamoto@gmail.com
NO
2017 | Year | 10 | Month | 11 | Day |
Unpublished
No longer recruiting
2017 | Year | 09 | Month | 29 | Day |
2021 | Year | 07 | Month | 07 | Day |
2017 | Year | 10 | Month | 26 | Day |
2023 | Year | 04 | Month | 19 | Day |
2017 | Year | 10 | Month | 11 | Day |
2025 | Year | 04 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033711